000304586 001__ 304586
000304586 005__ 20250916115009.0
000304586 0247_ $$2doi$$a10.1016/j.medj.2025.100753
000304586 0247_ $$2pmid$$apmid:40945500
000304586 0247_ $$2ISSN$$a2666-6340
000304586 0247_ $$2ISSN$$a2666-6359
000304586 037__ $$aDKFZ-2025-01909
000304586 041__ $$aEnglish
000304586 082__ $$a610
000304586 1001_ $$0P:(DE-HGF)0$$aFunk, Maximilian A$$b0
000304586 245__ $$aTargeting BCMA in CIDP: Valuable insights gained through multi-omics immune monitoring.
000304586 260__ $$aAmsterdam$$bElsevier$$c2025
000304586 3367_ $$2DRIVER$$aarticle
000304586 3367_ $$2DataCite$$aOutput Types/Journal article
000304586 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1757942450_16315
000304586 3367_ $$2BibTeX$$aARTICLE
000304586 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304586 3367_ $$00$$2EndNote$$aJournal Article
000304586 520__ $$aDong et al. present two patients with refractory chronic inflammatory demyelinating polyneuropathy (CIDP), who received treatment with B-cell-maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T cells.1 Extensive concomitant immune monitoring provides insights into the pathogenesis and mechanisms of relapse in CIDP that may help to determine the role of BCMA-targeted CAR-T cell therapy for this disease in the future.
000304586 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000304586 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000304586 7001_ $$0P:(DE-He78)da7efa4b1d86861f5e9964a8992eb36d$$aTheurich, Sebastian$$b1$$udkfz
000304586 773__ $$0PERI:(DE-600)3050845-9$$a10.1016/j.medj.2025.100753$$gVol. 6, no. 9, p. 100753 -$$n9$$p100753$$tMed$$v6$$x2666-6340$$y2025
000304586 909CO $$ooai:inrepo02.dkfz.de:304586$$pVDB
000304586 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000304586 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)da7efa4b1d86861f5e9964a8992eb36d$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000304586 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000304586 9141_ $$y2025
000304586 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-18
000304586 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-18
000304586 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMED-CAMBRIDGE : 2022$$d2024-12-18
000304586 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-18
000304586 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2024-12-18
000304586 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-18
000304586 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bMED-CAMBRIDGE : 2022$$d2024-12-18
000304586 9201_ $$0I:(DE-He78)MU01-20160331$$kMU01$$lDKTK Koordinierungsstelle München$$x0
000304586 980__ $$ajournal
000304586 980__ $$aVDB
000304586 980__ $$aI:(DE-He78)MU01-20160331
000304586 980__ $$aUNRESTRICTED